Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are female and aged 18 or older.
• People who have advanced solid tumours and have already received appropriate standard treatments for their tumour type, or where the treating doctor considers a clinical trial to be the best next option.
• People whose cancer has spread or come back in the local region, and where scans or other objective measures show the disease has continued to grow or progress during or after the most recent treatment.
• People who are generally well enough to carry out light activity (but not heavy physical work), with a life expectancy of at least 12 weeks.
• People who have at least one tumour lesion that can be measured or assessed on scans at the start of the trial and monitored over time.

Who may not be able to join:

• People who have received certain cancer treatments — including chemotherapy, other investigational drugs, or anti-cancer medicines — within 14 days or 5 half-lives of starting the trial drug (or 21 days for certain types), with some exceptions such as certain hormone-suppressing injections or bone-strengthening medicines.
• People who are taking prescription or non-prescription medicines, or herbal products, that are known to significantly affect how certain drugs are broken down in the body (moderate or strong CYP3A4/5 inhibitors or inducers), if these cannot be stopped before the trial starts and kept stopped throughout.
• People currently taking medicines known to carry a risk of a serious heart rhythm problem called Torsades de Pointes.
• People who have received a limited course of radiotherapy for pain relief within 1 week of the planned first dose.
• People who have had major surgery or a serious injury within 4 weeks before starting the trial, or who are expected to need major surgery or any surgery under general anaesthetic during the trial.
• People who still have unresolved side effects of a moderate or severe level (Grade 2 or higher) from previous cancer treatment, with the exception of hair loss. People with stable mild-to-moderate nerve-related side effects (Grade 2 neuropathy) may still be considered (confirm with trial site).
• People with life-threatening cancer spread to vital organs, or with uncontrolled cancer spread to the brain. People with treated and stable brain or spinal cord involvement who have been off steroids for at least 4 weeks may be considered (confirm with trial site).
• People with serious uncontrolled health conditions, such as uncontrolled high blood pressure, active uncontrolled bleeding, serious active infections requiring intravenous antibiotics, or active hepatitis B, hepatitis C, or HIV requiring antiviral treatment.
• People with certain heart conditions, including an abnormal heart rhythm measurement on ECG (resting QTcF greater than 470 milliseconds), significant abnormalities in heart rhythm or electrical conduction, or risk factors for dangerous heart rhythm problems such as symptomatic heart failure, a hereditary long QT condition, or a close family member who died suddenly and unexpectedly before age 40.
• People with reduced heart pumping function (heart pumping less than 50% efficiency), or who have had a heart attack, unstable chest pain, significant heart failure, stroke, or mini-stroke in the past 6 months, or certain heart procedures such as bypass surgery, angioplasty, or a stent.
• People with uncontrolled high blood pressure.
• People whose blood test results show that bone marrow or organ function is not adequate (confirm with trial site for specific values).
• People with persistent severe nausea and vomiting, uncontrolled long-term gut conditions, or a history of significant bowel removal surgery that could prevent the trial medicine from being properly absorbed.
• People with a known allergy or hypersensitivity to the trial drug (AZD8421) or to drugs with a similar structure.
• People who have previously been treated with AZD8421, or with any drug belonging to certain specific drug classes targeted by this trial (CDK2-selective inhibitors, PKMYT1 inhibitors, or WEE1 inhibitors).
• People who are currently pregnant, breastfeeding, or planning to become pregnant. People of childbearing potential must agree to use at least one highly effective method of contraception.

Important: Always verify eligibility with the trial site directly before applying.